LYT-100 (Deupirfenidone) for Idiopathic Pulmonary Fibrosis
(ELEVATE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests LYT-100, a new drug, in adults aged 40+ with Idiopathic Pulmonary Fibrosis who haven't been treated before. It aims to see if the drug can slow down the decline in lung function.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that patients who have been on nintedanib for less than 6 months can participate, suggesting that some medications might be allowed.
Is LYT-100 (Deupirfenidone) safe for humans?
What data supports the effectiveness of the drug LYT-100 for idiopathic pulmonary fibrosis?
Who Is on the Research Team?
Camilla Graham, MD
Principal Investigator
PureTech
Are You a Good Fit for This Trial?
This trial is for adults with Idiopathic Pulmonary Fibrosis (IPF) who are new to treatment or have had less than 6 months of a specific drug. They must be able to follow the study's procedures and not use tobacco products, including vaping. People with other lung diseases, recent serious heart issues, hospitalization due to COVID-19 or IPF flare-ups, or certain infections can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LYT-100, pirfenidone, or placebo daily for up to 183 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term extension
Participants may opt into continuation of treatment to evaluate tolerability and long-term safety
What Are the Treatments Tested in This Trial?
Interventions
- LYT-100
- LYT-100 (Deupirfenidone)
- Pirfenidone
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
PureTech
Lead Sponsor